Chimerix
pivotal phase action trial design primary overall survival secondary steroid response performance day day weekly day yale | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
17 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
pivotal phase action trial design primary overall survival day | Chimerix
Investor Presentation
March 2023
pivotal phase action trial design primary overall survival day | Chimerix
Related slides by other companies
Ocuphire Pharma
Investor Day
January 2022
zeta phase design placebo bid | Ocuphire Pharma
Equillium
Investor Presentation
February 2024
phase study of in adults with moderate to severe potential target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
AN2 Therapeutics
Investor Presentation
March 2025
in august announced phase top line results in mac | AN2 Therapeutics
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights